JP2021529732A5 - - Google Patents

Info

Publication number
JP2021529732A5
JP2021529732A5 JP2020569956A JP2020569956A JP2021529732A5 JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5 JP 2020569956 A JP2020569956 A JP 2020569956A JP 2020569956 A JP2020569956 A JP 2020569956A JP 2021529732 A5 JP2021529732 A5 JP 2021529732A5
Authority
JP
Japan
Prior art keywords
administration
pharmaceutical composition
composition according
esketamine
days
Prior art date
Application number
JP2020569956A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020003195A5 (https=
JP2021529732A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/055453 external-priority patent/WO2020003195A1/en
Publication of JP2021529732A publication Critical patent/JP2021529732A/ja
Publication of JPWO2020003195A5 publication Critical patent/JPWO2020003195A5/ja
Publication of JP2021529732A5 publication Critical patent/JP2021529732A5/ja
Priority to JP2024000939A priority Critical patent/JP2024041855A/ja
Pending legal-status Critical Current

Links

JP2020569956A 2018-06-27 2019-06-27 大うつ病性障害の処置方法 Pending JP2021529732A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024000939A JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862690419P 2018-06-27 2018-06-27
US62/690,419 2018-06-27
US201862698323P 2018-07-16 2018-07-16
US62/698,323 2018-07-16
US201862741564P 2018-10-05 2018-10-05
US62/741,564 2018-10-05
US201862769264P 2018-11-19 2018-11-19
US62/769,264 2018-11-19
PCT/IB2019/055453 WO2020003195A1 (en) 2018-06-27 2019-06-27 Method of treating major depressive disorder

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024000939A Division JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Publications (3)

Publication Number Publication Date
JP2021529732A JP2021529732A (ja) 2021-11-04
JPWO2020003195A5 JPWO2020003195A5 (https=) 2022-04-25
JP2021529732A5 true JP2021529732A5 (https=) 2022-04-25

Family

ID=67909427

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020569956A Pending JP2021529732A (ja) 2018-06-27 2019-06-27 大うつ病性障害の処置方法
JP2024000939A Pending JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024000939A Pending JP2024041855A (ja) 2018-06-27 2024-01-09 大うつ病性障害の処置方法

Country Status (11)

Country Link
US (2) US12036189B2 (https=)
EP (1) EP3813807A1 (https=)
JP (2) JP2021529732A (https=)
KR (1) KR102793535B1 (https=)
CN (1) CN112188889A (https=)
AU (1) AU2019293515B2 (https=)
BR (1) BR112020023882A2 (https=)
CA (1) CA3103440A1 (https=)
IL (1) IL278759B2 (https=)
MX (1) MX2020012475A (https=)
WO (1) WO2020003195A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3043785T1 (sl) 2013-09-13 2022-02-28 National University Corporation Chiba University Uporaba R-ketamina in njegove soli kot farmacevtska sredstva
PL3505157T3 (pl) 2017-12-29 2022-04-11 Celon Pharma S.A. Kompozycja ketaminy w postaci suchego proszku do podawania dopłucnego w leczeniu depresji opornej na leczenie
JP7548669B2 (ja) 2018-02-15 2024-09-10 国立大学法人千葉大学 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物
AU2019262197B2 (en) 2018-05-04 2024-12-19 Perception Neuroscience, Inc. Methods of treating substance abuse
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
US12364672B2 (en) 2018-10-11 2025-07-22 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
JP2023507926A (ja) 2019-12-30 2023-02-28 クレキシオ バイオサイエンシーズ エルティーディー． 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH535201A (de) 1969-12-19 1973-03-31 Bristol Myers Co Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
WO2007111880A2 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007009888A1 (de) 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
AU2008286914B2 (en) 2007-08-13 2014-10-02 Ohemo Life Sciences Inc. Abuse resistant drugs, method of use and method of making
NZ589764A (en) 2008-05-09 2012-10-26 Univ Emory NMDA receptor antagonists for the treatment of neuropsychiatric disorders
US20110038807A1 (en) 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder
PE20141906A1 (es) 2012-03-12 2014-12-05 Janssen Pharmaceutica Nv Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento
AU2013285988A1 (en) 2012-07-06 2015-02-12 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
WO2014020155A1 (en) 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
US9468611B2 (en) 2012-09-27 2016-10-18 Relmada Therapeutics, Inc. d-Methadone for the treatment of psychiatric symptoms
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
US9913803B2 (en) 2013-08-26 2018-03-13 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
WO2015051259A1 (en) 2013-10-04 2015-04-09 Impax Laboratories, Inc. Pharmaceutical compositions and methods of use
EA032013B1 (ru) 2013-10-31 2019-03-29 Сайма Лэбс Инк. Препятствующие злоупотреблению гранулированные лекарственные формы с немедленным высвобождением
DK3272338T3 (da) 2014-04-17 2020-11-02 Develco Pharma Schweiz Ag Oral doseringsform for ketamin
CN107208133A (zh) * 2014-09-15 2017-09-26 詹森药业有限公司 用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
AU2015343083B2 (en) 2014-11-04 2020-07-23 Acadia Pharmaceuticals Inc. Neuro-attenuating ketamine and norketamine compounds, derivatives thereof, and methods
JP6696994B2 (ja) 2014-12-08 2020-05-20 クレシオ・バイオサイエンシズ・リミテッド 即放性乱用抑止性顆粒剤形
US20160332962A1 (en) * 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
US20160338977A1 (en) * 2015-05-20 2016-11-24 Janssen Pharmaceutica Nv Methods and kits for treating depression
WO2017041112A1 (en) 2015-09-04 2017-03-09 Cyprus Therapeutics, Inc. Ketamine and cytochrome p 450 inhibitor combinations
EP3377050A4 (en) 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20190240184A1 (en) 2016-10-27 2019-08-08 National University Corporation Chiba University Pharmaceutical applications for (s)-norketamine and salts thereof
ES2991544T3 (es) 2016-11-30 2024-12-04 Wolfson Philip E Ketamina para el tratamiento de síntomas relacionados con la menstruación
EP3641742B1 (en) 2017-06-23 2026-03-25 Ketabon GmbH Hydroxynorketamine for the use in the treatment of depression
MX2020003546A (es) 2017-10-10 2020-08-03 Douglas Pharmaceuticals Ltd Formulacion farmaceutica de liberacion prolongada y metodos de tratamiento.
MX2020006650A (es) 2017-12-22 2020-11-06 Janssen Pharmaceuticals Inc Esketamina para el tratamiento de la depresión.
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
EP3923920A4 (en) 2019-08-05 2022-11-23 The Ketamine Research Foundation KETAMINE FOR THE TREATMENT OF SYMPTOMS AND DISORDERS AFTER CHILDREN
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Similar Documents

Publication Publication Date Title
JP2021529732A5 (https=)
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
Montgomery et al. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability
Cutler et al. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial
SK14612003A3 (sk) Použitie enantiomérne čistého escitalopramu a farmaceutický prostriedok s obsahom escitalopramu
Silva Filho et al. Comment on “The importance of physical exercise during the coronavirus (COVID-19) pandemic”
JPWO2020003195A5 (https=)
Lu et al. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series
EP3393517B1 (en) Acetylsalicylic acid for use in the treatment of moderate to severe influenza
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
Nikitina et al. OPTIMIZATION OF PHARMACOTHERAPY STRATEGY FOR TREATMENT-RESISTANT DEPRESSION
Alavi et al. Tranquilizer/Anxiolytics: Pregabalin
UA112652C2 (uk) Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції
Baker et al. 35304 safety and efficacy of COVID-19 vaccination in psoriasis patients
Bedard et al. P0174-Mindfulness-based cognitive therapy reduces depression symptoms in people with a traumatic brain injury: Results from a pilot study
Sharma et al. POS-416 TREATING HCV INFECTION IN CHRONIC KIDNEY DISEASE IN DEVELOPING COUNTRY: OUR EXPERIENCE WITH LIMITED RESOURCES
RU2000129499A (ru) Лечение депрессии и фармацевтические препараты для этой цели
Cooper et al. Improved health-related quality of life (HRQoL) and bleeding scores with oral bruton tyrosine kinase (BTK) inhibitor rilzabrutinib in the open-label (OL) period of the multicenter Phase 3 LUNA3 study in adults with immune thrombocytopenia (ITP)
Zhang et al. A Phase 2 Dose-Finding Trial of MY008211A in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria and Signs of Active Hemolysis
Downey A New Way To Manage Depression Without Drugs
Vieta Why do we consider major depressive disorder to be a chronic illness?
Al-Noaemi Mohammed et al. Drug Repositioning For The Prophylaxis And Treatment of COVID-19
TW202539680A (zh) 組合物在製備用於治療至少一種癌症的用途
Bauer et al. P0173-Effect of once-daily extended release Quetiapine Fumarate (Quetiapine XR) as add-on to antidepressants in major depressive disorder (MDD)
JPWO2024010592A5 (https=)